A Novel Preventive Treatment Against C Difficile Infection

  1. ImmuniMed inc., is a clinical stage Biopharmaceutical company engaged in a phase 2 clinical trial of a novel Antibody Cure for C Difficile Infection (CDI), where we have shown safe and reliable results that can now be applied to a novel Preventive against C Difficile infection.


  2. ImmuniMed Inc. has approved Patents for our CDI treatment in Canada, the U. S. and EU.


  3. Our Antibody treatment has already cured many patients in our ongoing phase 2 clinical trial and results from initial Compassionate Grounds trials were 94% effective in treating 106 CDI patients.


  4. Certain favorable tax advantages may be available.


  5. We expect Fast Tract assistance from the FDA as C Difficile Infection is considered an unmet medical need, requiring better solutions.


  6. ImmuniMed Inc anticipates having the capacity to produce enough Antibodies to prevent C Difficile infection on a global scale.


  7. Patients are often warned of contracting C Diff when taking broad spectrum antibiotics but there is no preventive treatment. We intend to solve this problem.

  8. Vaccines are used to prevent infection and typically stimulate a systemic immune response, with protective antibodies circulating in the blood stream. C Difficile is a bacterial infection of the gut, where systemic antibodies would be less effective. Both Pfizer and Sanofi Pasteur have recently announced the failure of their experimental C Diff vaccines to reach their successful end point of preventing C Diff infection.Our oral dose antibodies being directly targeted to the gut, will be a superior preventive application.

  9. We believe ImmuniMed Inc. has high upside value potential as the only preventive treatment for C Difficile infection. The first will be the prevention of C Difficile recurrence, a common problem associated with this disease, where alternatives range in price from $4,000 to $17,500 per one time treatment. And these can not be used to prevent the initial infection. Next is preventing hospital acquired infection, where some 300,000 North Americans are afflicted annually. And finally is the community application, where every person taking an antibiotic prescription is a potential user.


  10. As the World’s first successful treatment using Oral Dosed antibodies, we believe this will open the door for many other preventive treatments.